Stereotactic Ablative Radiation Therapy for Oligometastatic Non-Small Cell Lung Cancer, Subset Analysis of a Prospective Phase II Clinical Trial

Metastatic lung cancer has long represented a therapeutic challenge, with treatment primarily consisting of systemic chemotherapy, with limited long-term survival. Patients with limited sites ( ≤ 5) of metastatic disease, known as oligometastatic disease, may derive improved outcomes from aggressive local therapy. Stereotactic ablative radiation therapy (SABR) represent a promising new method of conformal aggressive treatment to oligometastic disease. Herein we report analysis of a prosp ective multi-center phase II trial assess the safety and feasibility of SABR for oligometastatic non-small-cell lung cancer.

Source: International Journal of Radiation Oncology * Biology * Physics - July 19, 2019 Category: Radiology Authors: P. Sutera, R. Kalash, D.A. Clump, D. D'Ambrosio, A.M. Mihai, S.A. Burton, D.E. Heron Tags: Publish Only Source Type: research